imidazolone and Uremia

imidazolone has been researched along with Uremia* in 4 studies

Trials

1 trial(s) available for imidazolone and Uremia

ArticleYear
Relation between different treatment modalities and genomic damage of end-stage renal failure patients.
    Kidney & blood pressure research, 2006, Volume: 29, Issue:1

    Patients with end-stage renal disease display enhanced genomic damage. We investigated the relation between genomic damage and different treatment modalities.. In a longitudinal study two groups of patients were analyzed in monthly intervals. We assessed the initiation of hemodialysis in 5 conservatively treated patients, and a switch from hemodialysis to hemodiafiltration in 7 patients. DNA damage was investigated in peripheral blood lymphocytes by micronucleus frequency and by comet assay analysis. With regard to potential genotoxicity of advanced glycation end products (AGEs), levels of imidazolone A and AGE-associated fluorescence (AGE-FL) were determined.. The initiation of hemodialysis did not alter the genomic damage. In patients who switched from hemodialysis to hemodiafiltration, a small but significant reduction in the comet assay but not in the micronucleus frequency was observed. Elevated plasma levels of imidazolone A and AGE-FL were not influenced by the treatment modalities.. In our small patient group no major reduction of the elevated genomic damage could be reached. Disease factors not influenced by altered dialysis modalities may have contributed considerably in our patient group. The persisting high levels of DNA damage suggest a need for further improvement. Inhibiting AGE formation may be one promising way for the future.

    Topics: Aged; Comet Assay; DNA Damage; Genome, Human; Glycation End Products, Advanced; Hemodiafiltration; Humans; Imidazoles; Kidney Failure, Chronic; Longitudinal Studies; Lymphocytes; Male; Micronuclei, Chromosome-Defective; Middle Aged; Renal Dialysis; Treatment Outcome; Uremia

2006

Other Studies

3 other study(ies) available for imidazolone and Uremia

ArticleYear
Immunochemical detection of imidazolone in uremia and rheumatoid arthritis.
    Clinica chimica acta; international journal of clinical chemistry, 2000, Volume: 300, Issue:1-2

    The advanced glycation end-product imidazolone is formed by reaction of arginine with 3-deoxyglucosone (3-DG), a reactive intermediate of the Maillard reaction, whose formation is non-oxidative. Using an antibody specific to this 3-DG-derived AGE, we demonstrated the presence of imidazolone-modified proteins in vivo in the urine and dialysate of patients with chronic renal failure, in the synovial fluid of patients with rheumatoid arthritis, as well as in vitro in human serum and human serum albumin incubated with glucose. Furthermore, we could show that in uremic patients the dimeric form of beta(2)-microglobulin is more susceptible to imidazolone modification than the monomeric one. Thus, the immunochemical detection of imidazolone may be a good marker for 3-DG-derived AGE modification in vivo and in vitro permitting a differentiation between the oxidative and the non-oxidative pathway of AGE generation.

    Topics: Adult; Aged; Arthritis, Rheumatoid; Blotting, Western; Electrophoresis, Polyacrylamide Gel; Female; Glycation End Products, Advanced; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Uremia

2000
Increased erythrocyte 3-DG and AGEs in diabetic hemodialysis patients: role of the polyol pathway.
    Kidney international, 1999, Volume: 55, Issue:5

    3-Deoxyglucosone (3-DG) accumulating in uremic serum plays an important role in the formation of advanced glycation end products (AGEs). To determine if 3-DG is involved in the formation of intracellular AGEs, we measured the erythrocyte levels of 3-DG and AGEs such as imidazolone and N epsilon-carboxymethyllysine (CML) in hemodialysis (HD) patients with diabetes. Further, to determine if the polyol pathway is involved in the formation of erythrocyte 3-DG and AGEs, an aldose reductase inhibitor (ARI) was administered to these patients.. The erythrocyte levels of sorbitol, 3-DG, imidazolone, and CML were measured in ten diabetic HD patients before and after treatment with ARI (epalrestat) for eight weeks, and were compared with those in eleven healthy subjects. 3-DG was incubated in vitro with hemoglobin for two weeks to determine if imidazolone and CML are formed by reacting 3-DG with hemoglobin.. The erythrocyte levels of sorbitol, 3-DG, imidazolone, and CML were significantly elevated in diabetic HD patients as compared with healthy subjects. The erythrocyte levels of 3-DG significantly decreased after HD, but sorbitol, imidazolone or CML did not. The administration of ARI significantly decreased the erythrocyte levels of sorbitol, 3-DG and imidazolone, and tended to decrease the CML level. Imidazolone was rapidly produced in vitro by incubating 3-DG with hemoglobin, and CML was also produced, but less markedly as compared with imidazolone.. The erythrocyte levels of 3-DG and AGEs are elevated in diabetic HD patients. The administration of ARI reduces the erythrocyte levels of 3-DG and AGEs, especially imidazolone, as well as sorbitol. Thus, 3-DG and AGEs, especially imidazolone, in the erythrocytes are produced mainly via the polyol pathway. ARI may prevent diabetic and uremic complications associated with AGEs.

    Topics: Adult; Aged; Aldehyde Reductase; Arginine; Creatinine; Deoxyglucose; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Erythrocytes; Female; Glycation End Products, Advanced; Hemoglobins; Humans; Imidazoles; In Vitro Techniques; Lysine; Male; Middle Aged; Polymers; Renal Dialysis; Sorbitol; Uremia

1999
Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl)lysine in aortas of hemodialysis patients.
    Cellular and molecular biology (Noisy-le-Grand, France), 1998, Volume: 44, Issue:7

    The modification of long-lived proteins with advanced glycation endproducts (AGEs) has been hypothesised to contribute to the development of pathologies associated with uremia. Imidazolone and N(epsilon)-(carboxymethyl)lysine (CML) are common epitopes of AGE-modified proteins. Imidazolone is a reaction product of arginine with 3-deoxyglucosone (3-DG) which is markedly accumulated in uremic serum. CML is produced by glycoxidation, and represents a marker of oxidative stress. The specificity of anti-imidazolone antibody that we had developed was further examined using ELISA. The antibody reacted only with imidazolone derived from 3-DG and arginine, but did not react at all with the other imidazolone-like compounds such as reaction products of glyoxal, methylglyoxal, glucosone with arginine or a reaction product of 3-DG with creatine. Further, to determine if AGEs are involved in the development of atherosclerosis in hemodialysis (HD) patients, we studied the localisation of imidazolone and CML in the aortas obtained from HD patients by immunohistochemistry using the anti-imidazolone and anti-CML antibodies. Imidazolone and CML were localised in all atherosclerotic aortic walls of the HD patients. In conclusion, imidazolone and CML are localised in the characteristic lesions of atherosclerosis in HD patients. These results strongly suggest that imidazolone produced by 3-DG, and CML produced by glycoxidation may contribute to the development of atherosclerosis in uremic patients.

    Topics: Aged; Aorta; Arginine; Arteriosclerosis; Deoxyglucose; Female; Glyoxal; Humans; Imidazoles; Immunohistochemistry; Lysine; Male; Middle Aged; Pyruvaldehyde; Renal Dialysis; Uremia

1998